In vitro dissolution method for evaluation of buprenorphine in situ gel formulation: A technical note

AAPS PharmSciTech

Volumn 8, Issue 3, 2007, Pages

  Graves, Richard A ^a   Freeman, Thomas ^a   Mandal, Tarun K ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

Buprenorphine; Dissolution; Drug abuse; In situ gel; PLGA

Indexed keywords

BUPRENORPHINE; POLYGLACTIN; GLYCOLIC ACID DERIVATIVE; POLY (LACTIC CO GLYCOLIC ACID); POLY (LACTIC-CO-GLYCOLIC ACID); POLYSORBATE; UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; RELIABILITY; CHEMISTRY; SOLUBILITY;

BUPRENORPHINE; CHEMISTRY, PHARMACEUTICAL; GELS; GLYCOLATES; POLYSORBATES; SOLUBILITY;

EID: 34547893400     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0803062     Document Type: Article

References (25)

1. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science. 1980;207:657-659.
2. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in buprenorphine- versus methadone-maintained patients. J Nerv Ment Dis. 1998;186:35-43.
3. Rosen MI, Wallace EA, Mcmahon TJ, et al. Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend. 1994;35:141-149.
4. Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37:31-37.
5. Gaitini L, Moskovitz B, Katz E, Vaisberg A, Vaida S, Nativ O. Sublingual buprenorphine compared to morphine delivered by a patient-controlled analgesia system as postoperative analgesia after prostatectomy. Urol Int. 1996;57:227-229.
6. Kuhlman JJ,Jr, Lalani S, Jr, Magluilo J, Jr, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996;20:369-378.
7. Lindhardt K, Ravn C, Gizurarson S, Bechgaard E. Intranasal absorption of buprenorphine - in vivo bioavailability study in sheep. Int J Pharm. 2000;205:159-163.
8. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-2755.
9. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction. 1998;93:1385-1392.
10. Resnick RB, Resnick E, Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuropsychopharmacol Biol Psychiaty. 1991;15:531-538.
11. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-580.
12. Mello NK, Lukas SE, Kamien JB, Mendelson JH, Drieze J, Cone EJ. The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther. 1992;260:1185-1193.
13. Pickworth WB, Johnson RE, Holicky BA, Cone E. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther. 1993;53:570-576.
14. Mandal TK. Development of biodegradable drug delivery system to treat addiction. Drug Dev Ind Pharm. 1999;25: 773-779.
15. Resnick RB, Resnick E, Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:531-538.
16. Radomsky ML, Brouwer G, Floy BJ, et al. The controlled release of ganirelix from the Atrigel injectable implant system. Proc Int Symp Control Rel Bioact Mater 1993;20:458-459.
17. Mello NK, Lukas SE, Kamien JB, Mendelson JH, Drieze J, Cone EJ. The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther. 1992;260:1185-1193.
18. Pickworth WB, Johnson RE, Holicky BA, Cone EJ. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther. 1993;53:570-576.
19. Ruel-Gariepy E, Shive M, Bichara A, et al. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm. 2004;57:53-63.
20. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21:201-230.
21. Koizumi A, Fujii M, Kondoh M, Watanabe Y. Effect of N-methyl-2-pyrrolidone on skin permeation of estradiol. Eur J Pharm Biopharm. 2004;57:473-478.
22. Ravivarapu HB, Moyer KL, Dunn RL. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant. AAPS PharmSciTech [serial online]. 2000;1:El.
23. The National Alliance of Advocate for Buprenorphine Treatment. Suboxone (CIII). Available at: http://www.naabt.org/documents/packageinsert.pdf. Accessed: July 26, 2007.
24. Abdou HM. Effect of the test parameters on dissolution rate. In: Abdou HM, ed. Dissolution, Bioavailability, and Bioequivalence. Easton, PA: Mack Publishing Co; 1989:195.
25. Lagrange F, Pehourcq F, Baumevieille M, Begaud B. Determination of buprenorphine in plasma by liquid chromatography: application to heroin-dependent subjects. J Pharm Biomed Anal. 1998; 16:1295-1300.